Poisoning and Toxicity: The New Age

  • Kim Kwai
  • Patrick Hinfey


This case serves to help navigate providers through the steps of managing the critically ill, hypotensive, bradycardic toxicologic patient.


Hypotension Bradycardia Toxicology Calcium channel blocker Beta-blocker Glucagon High-dose insulin therapy Lipid emulsion Intralipid Clonidine 


  1. 1.
    Stanek EJ, Nelson CE, DeNofrio D. Amlodipine overdose. Ann Pharmacother. 1997;31(7–8):853–6. [PubMed].CrossRefGoogle Scholar
  2. 2.
    Craig CR, Stitzel RE. Modern pharmacology with clinical applications. 6th ed; Lippincott Williams & Wilkins, Philideplphia: 2004. p. 182–4.Google Scholar
  3. 3.
    Wang DW, Mistry AM, Kahlig KM, Kearney JA, Xiang J, George AL Jr. Propranolol blocks cardiac and neuronal voltage-gated sodium channels. Front Pharmacol. 2010;1:144.CrossRefGoogle Scholar
  4. 4.
    MacNeil DJ. The side effect profile of class III antiarrhythmic drugs; focus on d,l-sotalol. Am J Cardiol. 1997;80:90G–8G.CrossRefGoogle Scholar
  5. 5.
    Mani BK, Osborne-Lawrence S, Vijayaraghavan P, Hepler C, Zigman JM. β1-Adrenergic receptor deficiency in ghrelin-expressing cells causes hypoglycemia in susceptible individuals. J Clin Investig. 2016;126:3467–78. Scholar
  6. 6.
    Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis. 1984;26:413.CrossRefGoogle Scholar
  7. 7.
    Lawrenson JG, Kelly C, Lawrenson AL, Birch J. Acquired colour vision deficiency in patients receiving digoxin maintenance therapy. Br J Ophthalmol. 2002;86:1259–61.CrossRefGoogle Scholar
  8. 8.
    Manini AF, Nelson LS, Hoffman RS. Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study. Am J Cardiovasc Drugs. 2011;11:173–8.CrossRefGoogle Scholar
  9. 9.
    DigiFab [product monograph]. Ottawa: Canadian Pharmacists Association; Available:
  10. 10.
    McMillin GA, Owen WE, Lambert TL, De BK, Frank EL, Bach PR, et al. Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clin Chem. 2002;48(9):1580–4. PubMed PMID: 12194938.PubMedGoogle Scholar
  11. 11.
    Kearney TE. Digoxin-specific antibodies. In: Poisoning & drug overdose. 7th ed; BTG, a UK pharmaceutical company. 2017.Google Scholar
  12. 12.
    Bamshad MJ, Wasserman GS. Pediatric clonidine intoxications. Vet Hum Toxicol. 1990;32:220–3.PubMedGoogle Scholar
  13. 13.
    Seger D. Clonidine toxicity revisited. Clin Toxicol. 2002;40:145–55.Google Scholar
  14. 14.
    Alinejad S, Kazemi T, Zamani N, Hoffman RS, Mehrpour O. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577–600.Google Scholar
  15. 15.
    Seyler DE, Borowitz JL, Maickel RP. Calcium channel blockade by certain opioids. Fundam Appl Toxicol. 1983;3:536–42.CrossRefGoogle Scholar
  16. 16.
    Mintzer MZ, Griffiths RR. Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure. Psychopharmacology. 2005;178:259–67.CrossRefGoogle Scholar
  17. 17.
    Roberts T, Thompson J. Illegal substances in anaesthetic and intensive care practices. Contin Educ Anaesth Crit Care Pain Adv Access. 2012;16(3):226–229.Google Scholar
  18. 18.
    Waseem M, Perry C, Bomann S. Cholinergic crisis after rodenticide poisoning. West J Emerg Med. 2010;11(5):524–7.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Vohra R. Organophosphorus and carbamate insecticides. In: Poisoning & drug overdose. 7th ed;Lange, New York: 2017.Google Scholar
  20. 20.
    Ito S, Nakazato Y, Ohga A. Further evidence for the involvement of Na+ channels in the release of adrenal catecholamine: the effect of scorpion venom and grayanotoxin I. Br J Pharmacol. 1981;72(1):61–7.CrossRefGoogle Scholar
  21. 21.
    Chan TYK. Aconite poisoning. Clin Toxicol. 2009;47:279–85. Scholar
  22. 22.
    Lung D. Venlafaxine pharmacobezoar causing intestinal ischemia requiring emergent hemicolectomy. J Med Toxicol. 2011;7:232–5.CrossRefGoogle Scholar
  23. 23.
    Erickson CP, Olson KR. Case files of the medical toxicology fellowship of the California poison control system-San Francisco: calcium plus digoxin-more taboo than toxic? J Med Toxicol. 2008;4(1):33–9.CrossRefGoogle Scholar
  24. 24.
    Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003;41(5):595–602. Review. PubMed PMID: 14514004.CrossRefGoogle Scholar
  25. 25.
    Kerns W II. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25(2):309–31.CrossRefGoogle Scholar
  26. 26.
    Kline JA, Raymond RM, Leonova ED, Williams TC, Watts JA. Insulin improves heart function and metabolism during non-ischemic cardiogenic shock in awake canines. Cardiovasc Res. 1997;34:289–98. Scholar
  27. 27.
    Das UN. Insulin: an endogenous cardioprotector. Curr Opin Crit Care. 2003;9(5):375–83.CrossRefGoogle Scholar
  28. 28.
    Yuan TH, Kerns WP, Tomaszewski CA, Ford MD, Kline JA. Insulin-glucose as adjunctive therapy of severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol. 1999;37:463–74. Scholar
  29. 29.
    Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol. 2013;9(3):242–9. Scholar
  30. 30.
    Gourlaine H, Buneaux F, Borron W, Gouget B, Levillain P. Interference of methylene blue with CO-oximetry of hemoglobin derivatives. Clin Chem. 1997;43:1078–80.Google Scholar
  31. 31.
    Roderique JD, Van Dyck K, Holman B, Tang D, Chui B, Spiess BD. The use of high-dose hydroxocobalamin for vasoplegic syndrome. Ann Thorac Surg. 2014;97:1785–6.CrossRefGoogle Scholar
  32. 32.
    Fueyo L, Robles J, Aguilar I. Hemolysis index to detect degree of hydroxocobalamin interference with common laboratory tests. J Clin Lab Anal. 2017;31.CrossRefGoogle Scholar
  33. 33.
    Sutter M, Tereshchenko N, Rafii R, et al. Hemodialysis complications of hydroxocobalamin: a case report. J Med Toxicol. 2010;6:165–7.CrossRefGoogle Scholar
  34. 34.
    Ciechanowicz S, Patil V. Lipid emulsion for local anesthetic systemic toxicity. Anesthesiol Res Pract. 2012;2012:11. Scholar
  35. 35.
    Cave G, Harvey M. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. Acad Emerg Med. 2009;16:815–24.CrossRefGoogle Scholar
  36. 36.
    Armenian P, French D, Smollin C, Olson K, Wu AHB. Prolonged absorption from sustained-release verapamil preparation with documentation of serum levels and their response to intralipids. Clin Toxicol. 2010;48(6):646.Google Scholar
  37. 37.
    Mirtallo JM, et al. State of the art review: intravenous fat emulsions: current applications, safety profile, and clinical implications. Ann Pharmacother. 2010;44:688–700.CrossRefGoogle Scholar
  38. 38.
    Hayes BD, Gosselin S, Calello DP, et al. Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clin Toxicol. 2016;54:365–404.CrossRefGoogle Scholar
  39. 39.
    Lee HM, Archer JR, Dargan PI, Wood DM. What are the adverse effects associated with the combined use of intravenous lipid emulsion and extracorporeal membrane oxygenation in the poisoned patient? Clin Toxicol (Phila). 2015;53:145–50.CrossRefGoogle Scholar
  40. 40.
    St-Onge M, Dubé PA, Gosselin S. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol. 2014;52:926–44.CrossRefGoogle Scholar
  41. 41.
    Weir MA, Dixon SN, Fleet JL, Roberts MA, Hackam DG, Oliver MJ, et al. b-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol. 2015;26:987–96.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Kim Kwai
    • 1
  • Patrick Hinfey
    • 2
  1. 1.UC Davis Medical CenterSacramentoUSA
  2. 2.Newark Beth Israel Medical CenterNewarkUSA

Personalised recommendations